Biotech Values

[DewDiligence]

ABT-450/r+ABT-333+Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects

In other words, ABT was not spouting hot air six months when it stated during its Investor Day presentation that it was seeing “unprecedented” interim results in the PILOT and Co-PILOT studies (#msg-68216224).

Many investors and analysts think the story in ABT’s pharma business is just Humira. If the results in HCV pan out, these investors and analysts will have to change their tune.